Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

DNTT (F5U7V) Rabbit Monoclonal Antibody #66759

Filter:
  • WB

    Product Specifications

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 60
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    DNTT (F5U7V) Rabbit Monoclonal Antibody recognizes endogenous levels of total DNTT protein.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human DNTT protein.

    Background

    DNA nucleotidylexotransferase (DNTT), also known as terminal deoxynucleotidyl transferase (TdT), is a specific DNA polymerase that is expressed in immature and early B cells, pre-T lymphoid cells, and acute lymphoblastic leukemia cells (1,2). DNTT is expressed primarily in the central lymphoid organs, such as thymus and bone marrow. DNTT adds N-nucleotides to the V, D, and J exons of the T-cell receptor (TCR) and B-cell receptor (BCR) genes during V/D/J recombination, allowing for an extraordinary amount of structural diversity in antibodies and TCRs (2,3). Studies using DNTT knockout mice found greater than 10-fold reductions in TCR diversity compared to wild-type mice, resulting in increased susceptibility to infection (4).

    Recent work has focused on the role of DNTT in immune cell function and cancers (5). DNTT has been shown to play a role in the differentiation of stem cells into mucosal-associated invariant T cells (MAITs) (6). Patients with leukemias and lymphomas have high expression of DNTT (7,8), and low expression of DNTT is significantly associated with increased resistance to chemotherapy in B-cell acute lymphoblastic leukemia (B-ALL) patients (8).

    Alternate Names

    deoxynucleotidyltransferase, terminal; DNA nucleotidylexotransferase; DNTT; nucleosidetriphosphate:DNA deoxynucleotidylexotransferase; TDT; Terminal addition enzyme; Terminal deoxynucleotidyltransferase; terminal deoxyribonucleotidyltransferase; Terminal transferase

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.